
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8535676/publications.pdf Version: 2024-02-01



WEI-TING HWANG

#	Article	IF	CITATIONS
1	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	12.4	1,402
2	Gene Editing of <i>CCR5</i> in Autologous CD4 T Cells of Persons Infected with HIV. New England Journal of Medicine, 2014, 370, 901-910.	27.0	1,227
3	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine, 2018, 24, 563-571.	30.7	1,150
4	CRISPR-engineered T cells in patients with refractory cancer. Science, 2020, 367, .	12.6	872
5	Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells. Science Translational Medicine, 2012, 4, 132ra53.	12.4	555
6	B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma. Journal of Clinical Investigation, 2019, 129, 2210-2221.	8.2	513
7	Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 173.	7.1	334
8	Effects of Critical Care Nurses' Work Hours on Vigilance and Patients' Safety. American Journal of Critical Care, 2006, 15, 30-37.	1.6	310
9	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood, 2016, 128, 360-370.	1.4	190
10	PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nature Medicine, 2022, 28, 724-734.	30.7	171
11	Effects of <i>BRCA1</i> - and <i>BRCA2</i> -Related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. Clinical Cancer Research, 2015, 21, 211-220.	7.0	165
12	Longitudinal HIV sequencing reveals reservoir expression leading to decay which is obscured by clonal expansion. Nature Communications, 2019, 10, 728.	12.8	149
13	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight, 2018, 3, .	5.0	140
14	Diversity in Graduate Medical Education in the United States by Race, Ethnicity, and Sex, 2012. JAMA Internal Medicine, 2015, 175, 1706.	5.1	138
15	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. Blood Advances, 2019, 3, 2812-2815.	5.2	133
16	Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer, 2020, 139, 1-8.	2.0	92
17	Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy, 2018, 26, 269-279.	8.2	90
18	Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy. Clinical Cancer Research, 2016, 22, 3791-3800.	7.0	77

#	Article	IF	CITATIONS
19	Screening for Family Psychosocial Risk in Pediatric Cancer: Validation of the Psychosocial Assessment Tool (PAT) Version 3. Journal of Pediatric Psychology, 2018, 43, 737-748.	2.1	77
20	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. Blood, 2018, 132, 298-298.	1.4	73
21	Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer. Clinical Cancer Research, 2020, 26, 2354-2361.	7.0	70
22	Adjuvant Sandwich Chemotherapy Plus Radiotherapy vs Adjuvant Chemotherapy Alone for Locally Advanced Bladder Cancer After Radical Cystectomy. JAMA Surgery, 2018, 153, e174591.	4.3	68
23	Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non–Small Cell Lung Cancer. Cancer Immunology Research, 2019, 7, 896-909.	3.4	64
24	Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer. Gynecologic Oncology, 2021, 163, 246-253.	1.4	62
25	Lin-28 Homologue A (LIN28A) Promotes Cell Cycle Progression via Regulation of Cyclin-dependent Kinase 2 (CDK2), Cyclin D1 (CCND1), and Cell Division Cycle 25 Homolog A (CDC25A) Expression in Cancer. Journal of Biological Chemistry, 2012, 287, 17386-17397.	3.4	60
26	Underrepresentation of Women and Minorities in the United States IR Academic Physician Workforce. Journal of Vascular and Interventional Radiology, 2016, 27, 1837-1844.e2.	0.5	59
27	I Can't Breathe: The Continued Disproportionate Exclusion of Black Physicians in the United States Radiation Oncology Workforce. International Journal of Radiation Oncology Biology Physics, 2020, 108, 856-863.	0.8	52
28	Female Representation in the Academic Oncology Physician Workforce: Radiation Oncology Losing Ground to Hematology Oncology. International Journal of Radiation Oncology Biology Physics, 2017, 98, 31-33.	0.8	51
29	Neutrophilâ€ŧoâ€lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer, 2017, 123, 794-801.	4.1	51
30	Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. , 2020, 8, e000974.		49
31	Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis, 2016, 37, 177-187.	2.8	44
32	High Resolution Magnetic Resonance Imaging for Characterization of the Neuroligin-3 Knock-in Mouse Model Associated with Autism Spectrum Disorder. PLoS ONE, 2014, 9, e109872.	2.5	36
33	Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B Cell Lymphomas. Transplantation and Cellular Therapy, 2022, 28, 669-676.	1.2	36
34	No impact of breast magnetic resonance imaging on 15â€year outcomes in patients with ductal carcinoma in situ or earlyâ€stage invasive breast cancer managed with breast conservation therapy. Cancer, 2017, 123, 1324-1332.	4.1	35
35	Dose–response effects of aerobic exercise on estrogen among women at high risk for breast cancer: a randomized controlled trial. Breast Cancer Research and Treatment, 2015, 154, 309-318.	2.5	34
36	Exercise-Induced Dose-Response Alterations in Adiponectin and Leptin Levels Are Dependent on Body Fat Changes in Women at Risk for Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1195-1200.	2.5	33

#	Article	IF	CITATIONS
37	Association between mesothelioma and non-occupationalÂasbestos exposure: systematic review and meta-analysis. Environmental Health, 2018, 17, 90.	4.0	33
38	Factors that predict for representation of women in physician graduate medical education. Medical Education Online, 2019, 24, 1624132.	2.6	33
39	CCNE1 copy number is a biomarker for response to combination WEE1-ATR inhibition in ovarian and endometrial cancer models. Cell Reports Medicine, 2021, 2, 100394.	6.5	29
40	Association of Age with Efficacy of Immunotherapy in Metastatic Melanoma. Oncologist, 2020, 25, e381-e385.	3.7	27
41	Feasibility of monitoring advanced melanoma patients using cellâ€free <scp>DNA</scp> from plasma. Pigment Cell and Melanoma Research, 2018, 31, 73-81.	3.3	25
42	SECTM1 Produced by Tumor Cells Attracts Human Monocytes via CD7-Mediated Activation of the PI3K Pathway. Journal of Investigative Dermatology, 2014, 134, 1108-1118.	0.7	24
43	Cyclin-Dependent Kinase 4/6 Inhibition for the Treatment of Unresectable Mature Teratoma: Long-Term Follow-Up of a Phase II Study. Clinical Genitourinary Cancer, 2016, 14, 504-510.	1.9	24
44	Dynamic Contrast-Enhanced MRI–Derived Intracellular Water Lifetime (Ï,,i): A Prognostic Marker for Patients with Head and Neck Squamous Cell Carcinomas. American Journal of Neuroradiology, 2018, 39, 138-144.	2.4	24
45	CAR T cell viability release testing and clinical outcomes: is there a lower limit?. Blood, 2019, 134, 1873-1875.	1.4	24
46	Comparing GPS, Log, Survey, and Accelerometry to Measure Physical Activity. American Journal of Health Behavior, 2016, 40, 123-131.	1.4	23
47	Assessing Interpersonal and Communication Skills in Radiation Oncology Residents: A Pilot Standardized Patient Program. International Journal of Radiation Oncology Biology Physics, 2014, 88, 1129-1135.	0.8	22
48	The Synthetic Lignan Secoisolariciresinol Diglucoside Prevents Asbestos-Induced NLRP3 Inflammasome Activation in Murine Macrophages. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-14.	4.0	22
49	Randomized, phase II dose optimization study of chimeric antigen receptor (CAR) modified T cells directed against CD19 in patients (pts) with relapsed, refractory (R/R) CLL Journal of Clinical Oncology, 2016, 34, 3009-3009.	1.6	22
50	Diastolic dysfunction in tetralogy of Fallot: Comparison of echocardiography with catheterization. Echocardiography, 2018, 35, 1641-1648.	0.9	21
51	Capecitabine and lapatinib for the firstâ€ŀine treatment of metastatic/recurrent head and neck squamous cell carcinoma. Cancer, 2016, 122, 2350-2355.	4.1	20
52	Monitoring Integration over Time Supports a Role for Cytotoxic T Lymphocytes and Ongoing Replication as Determinants of Reservoir Size. Journal of Virology, 2016, 90, 10436-10445.	3.4	20
53	A mineralogical and chemical investigation of road dust in Philadelphia, PA, USA. Environmental Science and Pollution Research, 2020, 27, 14883-14902.	5.3	20
54	Women In Steady Exercise Research (WISER) Sister: Study design and methods. Contemporary Clinical Trials, 2015, 41, 17-30.	1.8	19

#	Article	IF	CITATIONS
55	Adjuvant Radiation for Locally Advanced Bladder Cancer? A Question Worth Asking. International Journal of Radiation Oncology Biology Physics, 2016, 94, 1040-1042.	0.8	19
56	Outcomes in Patients With Non–small-cell Lung Cancer With Brain Metastases Treated With Pembrolizumab-based Therapy. Clinical Lung Cancer, 2021, 22, 58-66.e3.	2.6	19
57	Comparative toxicity outcomes of protonâ€beam therapy versus intensityâ€modulated radiotherapy for prostate cancer in the postoperative setting. Cancer, 2019, 125, 4278-4293.	4.1	18
58	SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments. JAMA Oncology, 2022, 8, 164.	7.1	15
59	Validating a Local Failure Risk Stratification for Use in Prospective Studies of Adjuvant Radiation Therapy for Bladder Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 95, 703-706.	0.8	14
60	Disparities in staging prostate magnetic resonance imaging utilization for nonmetastatic prostate cancer patients undergoing definitive radiation therapy. Advances in Radiation Oncology, 2016, 1, 325-332.	1.2	14
61	Etirinotecan Pegol (NKTR-102) in Third-line Treatment of Patients With Metastatic or Recurrent Non–Small-cell Lung Cancer: Results of a Phase II Study. Clinical Lung Cancer, 2018, 19, 157-162.	2.6	14
62	Validation of the Spanish Version of the Psychosocial Assessment Tool (PAT) in Pediatric Cancer. Journal of Pediatric Psychology, 2018, 43, 1104-1113.	2.1	14
63	Initial report of the genitourinary and gastrointestinal toxicity of post-prostatectomy proton therapy for prostate cancer patients undergoing adjuvant or salvage radiotherapy. Acta Oncológica, 2018, 57, 1506-1514.	1.8	13
64	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. Lung Cancer, 2019, 127, 25-33.	2.0	13
65	Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. Scientific Reports, 2021, 11, 9984.	3.3	13
66	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. Blood, 2019, 134, 1863-1863.	1.4	13
67	Low apolipoprotein A-I levels in Friedreich's ataxia and in frataxin-deficient cells: Implications for therapy. PLoS ONE, 2018, 13, e0192779.	2.5	13
68	A Risk Prediction Model for Sporadic CRC Based on Routine Lab Results. Digestive Diseases and Sciences, 2016, 61, 2076-2086.	2.3	11
69	Sustained Virological Response Is Associated with a Decreased Risk of Posttransplant Diabetes Mellitus in Liver Transplant Recipients with Hepatitis C–Related Liver Disease. Liver Transplantation, 2018, 24, 1665-1672.	2.4	11
70	A randomized clinical trial comparing adjuvant radiation versus chemo-RT versus chemotherapy alone after radical cystectomy for locally advanced bladder cancer Journal of Clinical Oncology, 2016, 34, 356-356.	1.6	11
71	Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Childâ€Pugh B cirrhosis. Cancer Medicine, 2023, 12, 189-199.	2.8	11
72	Sociodemographic disparities in the utilization of proton therapy for prostate cancer at an urban academic center. Advances in Radiation Oncology, 2017, 2, 132-139.	1.2	10

5

#	Article	IF	CITATIONS
73	Acute Hospital Encounters in Cancer Patients Treated With Definitive Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2018, 101, 935-944.	0.8	10
74	First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma. Blood, 2019, 134, 49-49.	1.4	10
75	Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer Journal of Clinical Oncology, 2022, 40, 9022-9022.	1.6	10
76	Copper Oxide Nanoparticle-Induced Acute Inflammatory Response and Injury in Murine Lung Is Ameliorated by Synthetic Secoisolariciresinol Diglucoside (LGM2605). International Journal of Molecular Sciences, 2021, 22, 9477.	4.1	9
77	Air pollution and lung cancer survival in Pennsylvania. Lung Cancer, 2022, 170, 65-73.	2.0	9
78	Evaluating the effects of design parameters on the performances of phase I trial designs. Contemporary Clinical Trials Communications, 2019, 15, 100379.	1.1	8
79	A phase I trial of cyclosporine for hospitalized patients with COVID-19. JCI Insight, 2022, 7, .	5.0	8
80	Geographic Differences in Lung Cancer Incidence: A Study of a Major Metropolitan Area within Southeastern Pennsylvania. International Journal of Environmental Research and Public Health, 2020, 17, 9498.	2.6	7
81	CART22-65s Co-Administered with huCART19 in Adult Patients with Relapsed or Refractory ALL. Blood, 2021, 138, 469-469.	1.4	7
82	Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC—Results From a Prospective Pilot Study. JTO Clinical and Research Reports, 2022, 3, 100301.	1.1	7
83	Environmental exposomics and lung cancer risk assessment in the Philadelphia metropolitan area using ZIP code–level hazard indices. Environmental Science and Pollution Research, 2021, 28, 31758-31769.	5.3	6
84	Effects of BRCA1/2 on Ovarian and Breast Cancer Survival—Response. Clinical Cancer Research, 2015, 21, 3807-3807.	7.0	5
85	Framework for assessment and phytoremediation of asbestos-contaminated sites. Environmental Science and Pollution Research, 2017, 24, 25912-25922.	5.3	5
86	RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma. Journal of Neuro-Oncology, 2019, 141, 95-102.	2.9	5
87	Radiation activates myeloperoxidase (MPO) to generate active chlorine species (ACS) via a dephosphorylation mechanism - inhibitory effect of LGM2605. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129548.	2.4	5
88	The aryl hydrocarbon receptor mediates sex ratio distortion in the embryos sired by TCDD-exposed male mice. Reproductive Toxicology, 2020, 94, 75-83.	2.9	5
89	Benefits and risks of contralateral prophylactic mastectomy in women undergoing treatment for sporadic unilateral breast cancer: a decision analysis. Breast Cancer Research and Treatment, 2015, 152, 217-226.	2.5	4
90	Differential elemental uptake in three pseudo-metallophyte C4 grasses in situ in the eastern USA. Plant and Soil, 2017, 416, 149-163.	3.7	4

#	Article	IF	CITATIONS
91	Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis. Journal of Molecular Diagnostics, 2021, 23, 1545-1552.	2.8	4
92	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. Blood, 2020, 136, 30-32.	1.4	4
93	Statistical Considerations for Analyses of Time-To-Event Endpoints in Oncology Clinical Trials: Illustrations with CAR-T Immunotherapy Studies. Clinical Cancer Research, 2022, 28, 3940-3949.	7.0	4
94	Long-term risk of second malignancies in women after breast conservation therapy for ductal carcinoma in situ or early-stage breast cancer. Breast Cancer Research and Treatment, 2018, 170, 45-53.	2.5	3
95	Risk factors for 30â€day readmission in adults hospitalized for pulmonary hypertension. Pulmonary Circulation, 2020, 10, 1-14.	1.7	3
96	Autologous CD4ÂT Lymphocytes Modified with a Tat-Dependent, Virus-Specific Endoribonuclease Gene in HIV-Infected Individuals. Molecular Therapy, 2021, 29, 626-635.	8.2	3
97	Randomized trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced bladder cancer after radical cystectomy Journal of Clinical Oncology, 2019, 37, 4507-4507.	1.6	3
98	Adoptive Immune Responses to Sars-Cov2 Vaccination in CART19 Treated Patients. Blood, 2021, 138, 1757-1757.	1.4	3
99	A Multicenter Analysis of Outcomes, Toxicities, and Patterns of Use with Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed/Refractory Aggressive B-Cell Lymphomas. Blood, 2021, 138, 2512-2512.	1.4	3
100	Identification of spatio-temporal clusters of lung cancer cases in Pennsylvania, USA: 2010–2017. BMC Cancer, 2022, 22, 555.	2.6	3
101	Preoperative predictors that impact the survival and outcome of patients undergoing secondary cytoreduction for ovarian cancer. Journal of Obstetrics and Gynaecology, 2018, 38, 395-401.	0.9	2
102	Understanding the predictive value of continuous markers for censored survival data using a likelihood ratio approach. BMC Medical Research Methodology, 2019, 19, 108.	3.1	2
103	Outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) with brain metastases treated with pembrolizumab-based therapy Journal of Clinical Oncology, 2020, 38, 9599-9599.	1.6	2
104	Prospective trial of adjuvant therapy after radical cystectomy for locally advanced bladder cancer: Analysis of the squamous cell carcinoma subgroup Journal of Clinical Oncology, 2020, 38, 524-524.	1.6	2
105	Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of Immunotherapy. Clinical Lung Cancer, 2022, 23, e301-e309.	2.6	2
106	Risk-Stratified Initial Salvage Therapy for Relapsed or Refractory Metastatic Germ Cell Tumors. Clinical Genitourinary Cancer, 2016, 14, 524-529.	1.9	1
107	Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure. Biomarkers in Medicine, 2017, 11, 547-556.	1.4	1
108	Reply to Neutrophilâ€ŧo″ymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710. Cancer, 2017, 123, 3856-3856.	4.1	1

#	Article	IF	CITATIONS
109	Optimal cutoffs for continuous biomarkers for survival data under competing risks. Communications in Statistics Part B: Simulation and Computation, 2019, 48, 1330-1345.	1.2	1
110	Incorporation of plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer Journal of Clinical Oncology, 2021, 39, 14-14.	1.6	1
111	A novel risk stratification to predict local-regional failures in urothelial carcinoma of the bladder after radical cystectomy Journal of Clinical Oncology, 2012, 30, 262-262.	1.6	1
112	Gene signature of antigen processing and presentation machinery (APM) as highly predictive of response to checkpoint blockade in lung cancer and melanoma Journal of Clinical Oncology, 2020, 38, 3121-3121.	1.6	1
113	Real-world outcomes after second-line treatment in non-small cell lung cancer (NSCLC) patients treated with immunotherapy Journal of Clinical Oncology, 2020, 38, e21620-e21620.	1.6	1
114	Rapid prediction of stem cell mobilization using volume and conductivity data from automated hematology analyzers. Transfusion, 2018, 58, 330-338.	1.6	0
115	OUP accepted manuscript. Journal of Pediatric Psychology, 2022, , .	2.1	0
116	Optimizing a risk stratification for local-regional failure after radical cystectomy using the SWOG 8710 cohort Journal of Clinical Oncology, 2014, 32, 297-297.	1.6	0
117	Risk-stratified treatment of patients with metastatic germ cell tumor with progression after first-line therapy Journal of Clinical Oncology, 2015, 33, 398-398.	1.6	0
118	Validating a local failure risk stratification for use in a prospective study of adjuvant radiation in bladder cancer Journal of Clinical Oncology, 2015, 33, 347-347.	1.6	0
119	Cyclin-dependent kinase 4/6 inhibition for the treatment of mature teratoma germ cell tumor: Long-term follow-up of a phase II study Journal of Clinical Oncology, 2016, 34, 474-474.	1.6	0
120	Neutrophil-to-lymphocyte ratio as a prognostic biomarker in bladder cancer: A REMARK-guided secondary analysis of SWOG 8710 Journal of Clinical Oncology, 2016, 34, 361-361.	1.6	0
121	Acute hospitalizations in cancer patients treated with definitive radiotherapy: A retrospective cohort study with implications for an urgent care clinic Journal of Clinical Oncology, 2016, 34, 312-312.	1.6	0
122	Impact of breast magnetic resonance imaging (MRI) on long-term outcome after breast conservation therapy (BCT) Journal of Clinical Oncology, 2016, 34, 1053-1053.	1.6	0
123	Prospective trial of adjuvant chemotherapy versus adjuvant radiation therapy for locally advanced bladder cancer after radical cystectomy Journal of Clinical Oncology, 2020, 38, 515-515.	1.6	0
124	Treatment patterns and outcomes in <i>ALK</i> or <i>ROS1</i> altered NSCLC: An ATOMIC Registry Study Journal of Clinical Oncology, 2022, 40, 9077-9077.	1.6	0